Promising Data ATIR Studies Presented by NIH Investigators

    AMSTERDAM, Nov. 28 /CNW/ - Kiadis Pharma announced today the presentation
of the results obtained so far in the physician initiated study led by
Dr. Stephan Mielke(*) and Dr. John Barrett(*) of the National Heart, Lung, and
Blood Institute (NHLBI) a department of the National Institutes of Health
(NIH) on Kiadis' lead product ATIR at the AABB annual meeting & TXPO 2007 in
Anaheim, California.
    According to the NHLBI investigators the challenge in the field of
allogeneic bone marrow transplantations lies with disease control, Graft
versus Host Disease (GvHD) control and donor availability. Doctors Barrett and
Mielke have focused on controlling GvHD whilst sparing the Graft versus
Leukemia (GvL) effect and also on increasing donor availability.
    The investigators have published the preclinical data showing promising
results with Kiadis Pharma's ATIR in eliminating alloreactive T cells from
donor grafts (Mielke et al. Blood, 2007). These results have led to the start
of a phase II study with ATIR by the NHLBI. This trial is designed to
demonstrate that ATIR treatment may overcome the need of immunosuppressant
prophylaxis post transplantation. Prophylaxis is currently standard practice
to prevent GvHD, but has a serious drawback, as it increases the chance of
infection and also the relapse rate. Thus ATIR does not only intend to prevent
GvHD, but could also reduce the rates of infection and relapse. Together,
these complications account for approximately 70 % of allogeneic transplant
related mortality.

    For the complete press release go to

    (*) Note
        Dr John Barrett is Chief of the Allotransplant Section at National
        Heart, Lung, and Blood Institute (NHLBI) of National Institutes of
        Health (NIH) in Bethesda, MD, USA, where the trial is being
        performed. Dr Stephan Mielke, who initiated this study as principal
        investigator at NHLBI, is currently working at the Julius-Maximilians
        University of Wurzburg, Germany and continues as the lead associate
        investigator on the protocol.

    English release is provided by Kiadis Pharma. Equivalent translations are
from a third party.

For further information:

For further information: Contact person: Kiadis Pharma B.V., Eefje
Simpelaar,, +31-20-8884815, +31-610829344

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890